Amarin (AMRN) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kamada (KMDA) has outperformed Amarin (AMRN) over the past year, gaining 14.7% versus a loss of 35.5%. Over five years, KMDA leads with a +22.7% price change compared with -85.5% for AMRN. Kamada is the larger company by market cap ($446.8 million vs $444.4 million), about 1.0 times the size.
On valuation, Amarin trades at a lower forward P/E (10.8x vs 13.3x for Kamada). Kamada pays a dividend yielding 7.24%, while Amarin does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -18.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | KMDA |
|---|---|---|
| Share price | $10.57 | $7.74 |
| Market cap | $444.39M | $446.85M |
| 1-day change | -6.13% | -1.15% |
| YTD return | -24.28% | +9.63% |
| 1-year return | -35.47% | +14.67% |
| 5-year return | -85.48% | +22.66% |
| P/E ratio (TTM) | — | 20.37 |
| Forward P/E | 10.79 | 13.34 |
| EPS (TTM) | $-0.80 | $0.38 |
| Dividend yield | 0.00% | 7.24% |
| Annual dividend | $0.00 | $0.56 |
| Revenue (latest FY) | $213.65M | $180.46M |
| Revenue growth (YoY) | -6.55% | +12.12% |
| Net income (latest FY) | $-38.80M | $20.20M |
| Gross margin | 56.57% | 42.34% |
| Operating margin | -23.48% | 14.54% |
| Net margin | -18.16% | 11.19% |
| 52-week high | $17.31 | $9.35 |
| 52-week low | $10.56 | $6.63 |
| Distance from 52-week high | -38.94% | -17.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +22.99% | +77.65% |
| Average volume | 79.50K | 121.87K |
| Shares outstanding | 42.04M | 57.73M |
| Employees | 80 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed AMRN by 50.1 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
- Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -18.2 cents for Amarin.
- Kamada grew revenue faster in its latest fiscal year (+12.12% vs -6.55%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
AMRN vs KMDA FAQ
Which is bigger, Amarin or Kamada?
Kamada (KMDA) is larger, with a market capitalization of $446.85M compared with $444.39M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or KMDA?
KMDA returned +14.67% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amarin or Kamada?
Kamada pays a dividend yielding 7.24%, while Amarin does not currently pay a regular dividend.
Are Amarin and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.